Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here

  • The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment.
  • The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide.
  • "Sotrovimab is no longer authorized to treat COVID-19 in any U.S. region due to increases in COVID-19 cases caused by the Omicron BA.2 sub-variant," the FDA said in a statement.
  • Related: FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant.
  • In a filing with the Securities and Exchange Commission, Vir Biotechnology said the companies were preparing a package of data to support the use of a higher dose of sotrovimab for the Omicron BA.2 sub-variant.
  • Vir and GSK still expect to commence two Phase 3 trials this quarter to assess the use of sotrovimab in uninfected immunocompromised patients to determine whether sotrovimab can prevent symptomatic Covid infection.
  • Price Action: GSK shares are up 1.86% at $45.40, and VIR stock is down 2.83% at $21.79 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.